CA2876636C - Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies - Google Patents

Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies Download PDF

Info

Publication number
CA2876636C
CA2876636C CA2876636A CA2876636A CA2876636C CA 2876636 C CA2876636 C CA 2876636C CA 2876636 A CA2876636 A CA 2876636A CA 2876636 A CA2876636 A CA 2876636A CA 2876636 C CA2876636 C CA 2876636C
Authority
CA
Canada
Prior art keywords
ifn
type
patient
antibody
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2876636A
Other languages
English (en)
French (fr)
Other versions
CA2876636A1 (en
Inventor
Brandon Higgs
Yihong Yao
Bing Wang
Lorin Roskos
Linda Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49758685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2876636(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CA2876636A1 publication Critical patent/CA2876636A1/en
Application granted granted Critical
Publication of CA2876636C publication Critical patent/CA2876636C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Databases & Information Systems (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Theoretical Computer Science (AREA)
  • Primary Health Care (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Mathematical Physics (AREA)
  • Software Systems (AREA)
CA2876636A 2012-06-13 2013-06-12 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies Active CA2876636C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659138P 2012-06-13 2012-06-13
US61/659,138 2012-06-13
PCT/US2013/045327 WO2013188494A1 (en) 2012-06-13 2013-06-12 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Publications (2)

Publication Number Publication Date
CA2876636A1 CA2876636A1 (en) 2013-12-19
CA2876636C true CA2876636C (en) 2022-09-13

Family

ID=49758685

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2876636A Active CA2876636C (en) 2012-06-13 2013-06-12 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Country Status (9)

Country Link
US (1) US9493570B2 (https=)
EP (1) EP2861621A4 (https=)
JP (5) JP2015526391A (https=)
KR (3) KR102320059B1 (https=)
CN (3) CN111494624A (https=)
AU (3) AU2013274389A1 (https=)
CA (1) CA2876636C (https=)
HK (1) HK1209758A1 (https=)
WO (1) WO2013188494A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035082T2 (en) * 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
KR100680048B1 (ko) * 2006-01-23 2007-02-08 쌍용자동차 주식회사 자동차 도장용 크레인의 구조
EP3359690A4 (en) 2015-10-09 2019-06-26 Genefron Ltd. METHODS AND KITS FOR PREDICTING AND DIAGNOSING CONGENITAL TRANSMISSION OF HUMAN CYTOMEGALOVIRUS (HCMV)
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
US20200031943A1 (en) 2017-03-21 2020-01-30 Austrianni Gmbh Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases
BR112020003670A2 (pt) 2017-08-22 2020-09-01 Sanabio, Llc receptores de interferon solúveis e usos dos mesmos
US11139051B2 (en) * 2018-10-02 2021-10-05 Origent Data Sciences, Inc. Systems and methods for designing clinical trials
EA202191133A1 (ru) * 2018-10-26 2021-07-12 Янссен Байотек, Инк. Сигнатуры интерферона типа i и способы их применения
JP7386877B2 (ja) * 2019-01-31 2023-11-27 イミューンセント バイオテクノロジー，インコーポレイテッド 新規の抗ｉｆｎａｒ１抗体
CN111892653A (zh) * 2019-07-03 2020-11-06 长春恒晓生物科技有限责任公司 制备粘病毒抗性蛋白1抗体及建立检测mx1方法
PT4192882T (pt) * 2021-04-23 2025-05-02 Astrazeneca Ab Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202402824D0 (en) * 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
HUE035082T2 (en) * 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
WO2006128210A1 (en) * 2005-06-03 2006-12-07 John Arthur Notaras A tiller
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
CA2651866C (en) 2006-05-11 2014-10-28 Universiteit Gent Sialoadhesin-related compositions and methods
EP2077858A4 (en) 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
CN101594882A (zh) * 2006-12-06 2009-12-02 米迪缪尼有限公司 干扰素α诱导的药代动力学标记物
PT2219452E (pt) * 2007-11-05 2016-01-26 Medimmune Llc Métodos de tratamento de esclerodermia
HRP20160855T1 (hr) * 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
US20110287022A1 (en) * 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
UA104868C2 (uk) * 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
US20120251546A1 (en) 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic

Also Published As

Publication number Publication date
CN111494624A (zh) 2020-08-07
AU2018206851B2 (en) 2020-07-30
KR102320059B1 (ko) 2021-11-01
JP6814238B2 (ja) 2021-01-13
JP2021167336A (ja) 2021-10-21
HK1209758A1 (en) 2016-04-08
JP2021042208A (ja) 2021-03-18
AU2018206851A1 (en) 2018-08-09
JP2015526391A (ja) 2015-09-10
KR102185237B1 (ko) 2020-12-02
KR20200133395A (ko) 2020-11-27
US20150158949A1 (en) 2015-06-11
CN104603152A (zh) 2015-05-06
CA2876636A1 (en) 2013-12-19
CN108310375A (zh) 2018-07-24
KR102185237B9 (ko) 2021-08-06
AU2013274389A1 (en) 2015-01-22
AU2020204613A1 (en) 2020-07-30
KR20210130270A (ko) 2021-10-29
JP7123225B2 (ja) 2022-08-22
AU2020204613B2 (en) 2021-10-07
KR20150035825A (ko) 2015-04-07
EP2861621A4 (en) 2016-01-20
EP2861621A1 (en) 2015-04-22
JP2018065845A (ja) 2018-04-26
JP2019112429A (ja) 2019-07-11
WO2013188494A1 (en) 2013-12-19
AU2018206851C1 (en) 2021-11-25
US9493570B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
AU2020204613B2 (en) Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
US12152075B2 (en) Treatment of renal cell carcinoma
JP5996549B2 (ja) 中和抗ｃｃｌ２０抗体
JP6949009B2 (ja) ヒトプログラム死リガンド２（ｐｄ−ｌ２）に結合する抗体およびその用途
AU2012341081B2 (en) Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
JP2018535394A (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
EP3359688B1 (en) Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
WO2012162367A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha
US20220155320A1 (en) Cytokine profiling analysis
JP2025520063A (ja) ヒトｃｃｒ８に結合する抗体
TW202229334A (zh) CD1a抗體及其用途
HK40034632A (en) Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
TR201903548T4 (tr) B-prekursör akut lenfoplastik lösemi hastalarının risk sınıflandırması.
HK1172061A (en) Methods for treating, diagnosing, and monitoring rheumatoid arthritis
HK1172061B (en) Methods for treating, diagnosing, and monitoring rheumatoid arthritis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180612

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523